Related Experiment Video
Updated: May 7, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Neoadjuvant Cetuximab Leading to a Complete Pathologic Response in Locally Advanced Lip Squamous Cell Carcinoma
Ruba Alchaikh Hassan1, Zahra Gafarzadeh1, Shiva Salmasi2
1Internal Medicine, Eisenhower Health, Rancho Mirage, USA.
This case study shows successful neoadjuvant cetuximab treatment for advanced vermillion lip squamous cell carcinoma (SCC) after PD-1 inhibitor failure. This approach offers a potential new treatment option for this rare cancer.
Area of Science:
- Oncology
- Dermatology
Background:
- Vermillion lip squamous cell carcinoma (SCC) is rare and often classified under cutaneous SCC (cSCC).
- Standard treatment protocols for this specific subtype are not well-established.
Observation:
- An 81-year-old male presented with locally advanced lower lip SCC involving the vermillion.
- The patient had previously failed treatment with a programmed cell death protein-1 (PD-1) inhibitor, cemiplimab.
Findings:
- Complete pathologic response achieved with neoadjuvant cetuximab.
- No signs of recurrence at 24-week follow-up.
- Positive surgical and cosmetic outcomes reported.
Implications:
- Cetuximab shows potential as a neoadjuvant therapy for vermillion lip cSCC.
- This case suggests a possible alternative treatment pathway for refractory cases.
- Clinical trials investigating cetuximab for vermillion lip SCC are warranted.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018